Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Non-Invasive Prenatal Testing Market Report by Product Type (Consumables, Instruments), Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, and Others), Technology (NGS, WGS, and Others), Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, and Others), Application (Trisomy, Microdeletion Syndrome, and Others), End-User (Hospitals, Diagnostic Laboratories, and Others), and Region 2024-2032
Report Format: PDF+Excel | Report ID: SR112024A2086
Buy Now
Market Overview:
The global non-invasive prenatal testing market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.0 Billion by 2032, exhibiting a growth rate (CAGR) of 14.6% during 2024-2032.
|
Report Attribute
|
Key Statistics
|
|---|---|
|
Base Year
|
2023
|
|
Forecast Years
|
2024-2032
|
|
Historical Years
|
2018-2023
|
|
Market Size in 2023
|
US$ 4.0 Billion |
|
Market Forecast in 2032
|
US$ 14.0 Billion |
| Market Growth Rate 2024-2032 | 14.6% |
Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.
The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global non-invasive prenatal testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, test type, technology, method, application and end-user.
Breakup by Product Type:
- Consumables
- Instruments
Breakup by Test Type:
- Materni 21
- Harmony
- Panaroma
- Verifi
- NIFTY
- Others
Breakup by Technology:
- NGS
- WGS
- Others
Breakup by Method:
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
- Fetal Cells in Maternal Blood Tests
- Others
Breakup by Application:
- Trisomy
- Microdeletion Syndrome
- Others
Breakup by End-User:
- Hospitals
- Diagnostic Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.
Report Coverage:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Units | US$ Billion |
| Segment Coverage | Product Type, Test Type, Technology, Method, Application, End-User, Region |
| Region Covered | North America, Asia Pacific, Europe, Latin America, Middle East and Africa |
| Countries Covered | United States, Canada, China, Japan, India, South Korea, Australia, Indonesia, Germany, France, United Kingdom, Italy, Spain, Russia, Brazil, Mexico |
| Companies Covered | Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global non-invasive prenatal testing market was valued at US$ 4.0 Billion in 2023.
We expect the global non-invasive prenatal testing market to exhibit a CAGR of 14.6% during 2024-2032.
The high prevalence of genetic disorders, coupled with the introduction of numerous awareness programs towards the availability of early diagnosis and treatment facilities, is primarily driving the global non-invasive prenatal testing market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective prenatal screening tests to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment.
Based on the product type, the global non-invasive prenatal testing market has been segmented into consumables and instruments, where consumables hold the majority of the total market share.
Based on the test type, the global non-invasive prenatal testing market can be divided into Materni 21, Harmony, Panaroma, Verifi, NIFTY, and others. Currently, Materni 21 test exhibits a clear dominance in the market.
Based on the technology, the global non-invasive prenatal testing market has been bifurcated into NGS, WGS, and others. Among these, NGS technology currently accounts for the majority of the global market share.
Based on the method, the global non-invasive prenatal testing market can be categorized into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests, fetal cells in maternal blood tests, and others. Currently, cell-free DNA in maternal plasma tests method holds the largest market share.
Based on the application, the global non-invasive prenatal testing market has been divided into trisomy, microdeletions syndrome, and others. Among these, trisomy accounts for the majority of the total market share.
Based on the end-user, the global non-invasive prenatal testing market can be segregated into hospitals, diagnostic laboratories, and others. Currently, diagnostic laboratories exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global non-invasive prenatal testing market include Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More